HomeAI · summaries
Storia in 2 fonti
Drug Combo for Lung Cancer Beats Pembrolizumab in First-Line Trial
Antibody-drug conjugate plus pembrolizumab superior to pembrolizumab alone in PD-L1 expressors
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
Drug Combo for Lung Cancer Beats Pembrolizumab in First-Line Trial
Antibody-drug conjugate plus pembrolizumab superior to pembrolizumab alone in PD-L1 expressors
- ·
morningstar.com
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
